As of June 9, 2025, Ionis Pharmaceuticals Inc (IONS) reports a Net Margin of -64.38%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Ionis Pharmaceuticals Inc's Net Margin
Over recent years, Ionis Pharmaceuticals Inc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | -64.38% |
| 2023-12-31 | -46.48% |
| 2022-12-31 | -45.91% |
| 2021-12-31 | -3.53% |
| 2020-12-31 | -60.92% |
This slight downward trend highlights how Ionis Pharmaceuticals Inc manages its overall profitability and cost control over time.
Comparing Ionis Pharmaceuticals Inc's Net Margin to Peers
To better understand Ionis Pharmaceuticals Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Ionis Pharmaceuticals Inc (IONS) | -64.38% |
| Halozyme Therapeutics Inc (HALO) | 43.74% |
| United Therapeutics Corp (UTHR) | 41.53% |
| Alkermes Plc (ALKS) | 23.56% |
| Sarepta Therapeutics Inc (SRPT) | 12.37% |
| TG Therapeutics Inc (TGTX) | 7.11% |
Compared to its competitors, Ionis Pharmaceuticals Inc's Net Margin is about average compared to peers, reflecting typical industry profitability.